Tibsovo

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.[1] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and for cholangiocarcinoma.[2][3][4][5] Ivosi... [wikipedia]